The approval of the 9-14 year old two dose vaccination program for the Merck East nine valent HPV vaccine will further expand the market size
王俊杰2017
发表于 2024-1-10 10:23:21
241
0
0
On January 9th, MSD announced that its nine valent human papillomavirus vaccine (brewing yeast) (trade name: Jiada Xiu 9) has been approved by the National Medical Products Administration of China for the second dose vaccination program (0, June December) for women aged 9-14 years old.
Merck said that this approval means that on the basis of the previous three dose vaccination program for 9-45 years old, the Jia Da Xiu 9 will add a two dose vaccination program for 9-14 years old, providing more economical and convenient health protection for more eligible women, helping them stay away from HPV infection related cervical cancer and cervical lesions.
In the industry's view, the age range of 9-14 years old is the "golden age" for receiving HPV vaccines. Currently, the penetration rate of HPV vaccines in this age group is relatively low. After the approval of the 9-14 year old two dose vaccination program for the nine valent HPV vaccine, it will help to further expand the market size of the nine valent HPV vaccine, as well as improve market penetration and accessibility. As the exclusive distributor of Merck's HPV vaccine, Zhifei Biotechnology is expected to benefit from the increase in the total demand for the nine valent HPV vaccine.
Teenagers are the primary recipients of HPV vaccines
It is reported that cervical cancer is one of the common gynecological malignancies. Its incidence rate and mortality are on the rise, which has become a serious public health problem threatening women's health. Almost all cervical cancer is associated with HPV infection, and vaccination can effectively prevent cervical cancer by preventing HPV infection. Meanwhile, cervical cancer is currently the only cancer in the world that can be prevented. Because the etiology of cervical cancer is clear, 99.7% of cervical cancer is caused by persistent infection of high-risk HPV.
Currently, getting vaccinated against HPV is the most economical and effective measure to prevent cervical cancer. Multiple authoritative guidelines indicate that adolescents are the primary recipients of HPV vaccines across all age groups.
As explicitly stated by the World Health Organization (WHO) in its Global Strategy to Accelerate the Elimination of Cervical Cancer, 90% of girls are required to complete HPV vaccination before the age of 15. The 2017 "HPV Vaccine: WHO Position Paper" pointed out that in order to prevent cervical cancer, WHO recommends that the primary target of HPV vaccination is girls aged 9-14 who have not engaged in sexual activity. According to the 2019 US "Adult HPV Vaccination: ACIP Update Recommendations," ACIP routinely recommends HPV vaccination for adolescents aged 11-12, starting from the age of 9. According to the 2017 Comprehensive Prevention and Control Guidelines for Cervical Cancer in China, the recommended age range for HPV vaccination in China is 9-45 years old women, with a focus on 13-15 year old girls.
In fact, 9-14 years old is considered the optimal age for receiving the HPV vaccine and is currently recognized as the "golden age" for receiving the HPV vaccine. In terms of the protective effect of vaccines, age is crucial, and the earlier vaccination, the better the immune effect obtained. At the same time, vaccinated individuals aged 9-14 are more likely to have no risk of HPV infection, resulting in a higher protective effect.
According to the clinical trial results previously released by Merck, the antibody positivity rate of the tetravalent HPV vaccine and the nine valent HPV vaccine for Chinese girls aged 9-19 reached 100%. At the same time, both vaccines can provide long-term protection for adolescents. After receiving the quadrivalent HPV vaccine for women aged 16 to 23, the protective effect is 100% after 14 years of follow-up; After receiving the nine valent HPV vaccine, women aged 9-15 years old were followed up for 11 years with a 100% protective effect.
The actual vaccination rate among the 9-14 year old population is very low
Although the age range of 9-14 is the golden age for receiving HPV vaccines, the penetration rate of HPV vaccines is not high in this age group.
Taking the data of Wuhan as an example, according to the news released on the official account of "Wuhan Disease Control and Health Promotion", from January to June 2023, Wuhan will receive 370000 doses of various HPV vaccines, including bivalent, tetravalent, and ninvalent vaccines.
Out of 370000 data points, 60000 data points were stratified and analyzed. Among the 60000 data points, women aged 9-15 received only 381 doses, accounting for 0.64%, which can be almost negligible; 1586 doses were administered to women aged 16-20, accounting for 2.64%; Women aged 21-25 received 5115 doses, accounting for 8.53%. The peak doses were administered to women aged 26-30, 31-35, and 36-40, with 14378 doses (23.96%), 20476 doses (34.12%), and 12933 doses (21.56%) respectively. Women aged 41-45 received 5131 doses, accounting for 8.55%.
According to data from Wuhan, the population aged 9-15 who require priority vaccination is actually the lowest among all age groups. In the industry's view, due to the low penetration rate, the approval of the 9-14 year old two dose vaccination program for the Merck Dong nine valent HPV vaccine is expected to release more vaccine resources. After the burden is reduced, the total demand for the nine valent HPV vaccine may actually increase.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Tesla Musk: Expected FSD to be approved and implemented in China before the end of the year
- Vaccine giant responds: nationwide suspension
- The Class 1 new drug introduced by Anjin with over 1 billion US dollars has been approved for clinical use
- JD Allianz Equity Transfer Approved: Allianz Insurance Group to Transfer 53.33% Equity of the Company to Allianz China Holdings
- Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
- Intel Technology is expected to complete $8.5 billion in financing by the end of the year; A total of 109 domestic online games were approved in September
- AMD releases Nvidia competitor AI chip expected market size of $500 billion over four years
- Johnson&Johnson's drug Zebaike has been approved in China
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
-
随着“银十”结束,各家造车新势力都交出了一份亮眼的成绩单。 理想领跑10月新势力交付榜,鸿蒙智行重回4万辆,零跑、深蓝、极氪、小鹏等单月交付量均创新高,岚图、阿维塔、智己等实现破万,但哪吒却消失在 ...
- fanadam
- 昨天 20:02
- 支持
- 反对
- 回复
- 收藏
-
【科技记者古尔曼:苹果计划于12月第一周发布iOS 18.2系统更新 带来更多人工智能功能】科技记者古尔曼透露,苹果计划于12月第一周发布iOS 18.2系统更新。iOS 18.2将为iPhone 15 Pro机型和所有iPhone 16机型带来更多 ...
- cristianna
- 前天 17:32
- 支持
- 反对
- 回复
- 收藏
-
为期超七周的大罢工终于落下帷幕。 当地时间11月4日,波音美国西海岸工厂工人们就改进后的合同提案投票。 随后,代表着波音超过33000名西雅图地区机械师的IAM工会经表决,以59%的同意票决定接纳波音提 ...
- cristianna
- 昨天 16:55
- 支持
- 反对
- 回复
- 收藏
-
近日,爱立信中国区总裁方迎在接受《经济参考报》记者采访时表示,5G技术在全球范围内得到了迅速发展,但面临商业潜力未能充分挖掘、网络运营难度较以往更高两大挑战。因此,运营商在继续5G网络部署的同时,应关 ...
- blueskybb
- 前天 15:05
- 支持
- 反对
- 回复
- 收藏